Proglumide selectively potentiates supraspinal μ1 opioid analgesia in mice Journal Article


Authors: Bodnar, R. J.; Paul, D.; Pasternak, G. W.
Article Title: Proglumide selectively potentiates supraspinal μ1 opioid analgesia in mice
Abstract: The cholecystokinin antagonist proglumide potentiates morphine analgesia. To understand more fully the opiate receptor subtypes involved with this effect, we investigated the effect of proglumide on spinal and supraspinal μ and spinal δ analgesia in mice. Proglumide alone had no effect on tailflick latencies, but increased, in a dose-dependent manner, tailflick latencies in morphine-tolerant mice. Proglumide also potentiated morphine analgesia in naive mice in a dose-dependent manner, with a maximal effect at 5-10 mg kg. Proglumide both shifted the dose-response curve for morphine analgesia to the left and prolonged morphine's duration of action. Proglumide increased the sensitivity of supraspinal μ1. receptor mechanisms of analgesia without influencing spinal mechanisms. Proglumide administered subcutaneously potentiated the analgesic actions of intracerebroventricular [D-Ala2MePhe4,Gly(ol)5]enkephalin (DAGO; (μ1), but not intrathecal DAGO (μ2) or (D-Pen2, D-Pen5]enkephalin (DPDPE; δ). The selective μ1. receptor antagonist naloxonazine blocked proglumide-enhanced morphine analgesia. © 1990.
Keywords: nonhuman; mouse; animal; mice; animal experiment; dose-response relationship, drug; morphine; analgesia; mu opiate receptor; receptors, opioid, mu; glutamine; reaction time; receptors; enkephalin, ala(2)-mephe(4)-gly(5)-; receptors, opioid, delta; naloxonazine; opioid receptors; intraperitoneal drug administration; cholecystokinin; subcutaneous drug administration; narcotics; receptors, opioid; intracerebroventricular drug administration; male; priority journal; article; enkephalin derivative; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; enkephalins; morphine dependence; enkephalin, d-penicillamine (2,5)-; intrathecal drug administration; μ1; proglumide
Journal Title: Neuropharmacology
Volume: 29
Issue: 5
ISSN: 0028-3908
Publisher: Pergamon-Elsevier Science Ltd  
Date Published: 1990-05-01
Start Page: 507
End Page: 510
Language: English
DOI: 10.1016/0028-3908(90)90174-p
PUBMED: 2162497
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 January 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gavril W Pasternak
    414 Pasternak
  2. Dennis J. Paul
    17 Paul